NCT04313608 : A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma

Trial Overview Read MoreRead more

This phase I trial is evaluating the safety and effectiveness of two targeted therapy drugs, each given in combination with chemotherapy for the treatment of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) that has gotten worse or not responded to prior treatment.
 

This trial is treating patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible patients will be assigned to one of two experimental arms of the trial (Arm A or Arm B). In Arm A, patients will receive up to 8, 21-day cycles of glofitamab in combination with gemcitabine and oxaliplatin, followed by up to 4 cycles of glofitamab monotherapy. In this Arm, a single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. In Arm B, patients will receive up to 8 cycles of mosunetuzumab in combination with gemcitabine and oxaliplatin, administered in 21-day cycles.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Clayton
Ms Micheleine Uhe
Micheleine.Uhe@monashhealth.org
03 9594 4044

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next